Abstract:Abstract Background The efficacy of neoadjuvant treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant remains unsatisfactory. This study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as a neoadjuvant treatment for patients with stage III-N2 EGFR-mutant non-small cell lung cancer (NSCLC). Patients and Methods The medical records of patients with III-N2 EGFR-mutant NSCLC who received neoadjuvant therapy with EGFR-TKI at Shanghai Chest Hospital from October 2011 to October 2022 were retrospectively reviewed. Patients with stage III-N2 EGFR-mutant NSCLC who received first-generation TKI combined with chemotherapy as neoadjuvant treatment were included in the combination group, and those who received EGFR-TKI monotherapy were included in the monotherapy group. The study assessed the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, disease-free survival (DFS), overall survival (OS), downstaging rates of pathologic lymph nodes (from stage N2 to N1 or N0), major pathologic response (MPR) rate, pathological complete response (PCR) rate, and safety. Results A total of 74 631 patients with EGFR-mutant NSCLC were screened, and 60 patients were included, 7 of whom did not undergo surgery after neoadjuvant targeted therapy. Of the remaining 53 patients, 15 received first-generation EGFR-TKI combined with chemotherapy as neoadjuvant treatment, and 38 received EGFR-TKI monotherapy. The median follow-up time was 44.12 months. The ORR was 50.0% (9/18) in the combination group and 40.5% (17/42) in the monotherapy group (P = .495). The MPR rate was 20.0% (3/15) and 10.5% (4/38) in the combination and monotherapy groups, respectively (P = .359). No patients achieved PCR in the combination group, while 3 (7.89%) attained PCR in the monotherapy group. The 2 groups did not differ in N2 downstaging rate (P = .459). The median DFS was not reached in the combination group, while it was 23.6 months (95% CI: 8.16-39.02) in the monotherapy group (P = .832). Adverse events observed were consistent with those commonly associated with the 2 treatments. Conclusion Combination therapy with first-generation EGFR-TKI and chemotherapy could be considered a neoadjuvant treatment option for patients with stage III-N2 EGFR-mutant NSCLC, exhibiting acceptable toxicity. However, regarding short-term efficacy, combination therapy did not demonstrate superiority over EGFR-TKI monotherapy. Long-term follow-up is warranted for a more accurate assessment of the DFS and OS.

Chemotherapy Influence Egfr Mutation Status for Chinese Patients with Regionally Advanced Non-Small Cell Lung Cancer

Influence of Chemotherapy on EGFR Mutation Status among Patients with Non-Small-cell Lung Cancer.

Alterations In Egfr And Related Genes Following Neo-Adjuvant Chemotherapy In Chinese Patients With Non-Small Cell Lung Cancer

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer

Ctdna Assessment of EGFR Mutation Status in Chinese Patients with Advanced Non-Small Cell Lung Cancer in Real-World Setting

Clinical Experience on Treatment of Advanced Lung Adenocarcinoma with Unknown EGFR Gene Status from a Tertiary Care Center in China

Real-world EGFR Testing in Patients with Stage IIIB/IV Non-Small-cell Lung Cancer in North China: A Multicenter, Non-Interventional Study.

[Role of EGFR Mutation Status in Patients with Stage III Non-Squamous Non-Small Cell Lung Cancer Treated with Chemoradiotherapy].

Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations

Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study

The efficacy and safety of EGFR-TKI combined with chemotherapy in NSCLC patients with EGFR co-mutation with other oncogenic alterations.

Analysis of EGFR Mutation in Chinese Non-Small Cell Lung Cancer Patients

The Mutation Profile of EGFR in Resectable Chinese Lung Cancer Patients.

Efficacy and Predictors of Egfr Tyrosine Kinase Inhibitors in Chinese Advanced Lung Adenocarcinoma: Analyses of 253 Cases from A Single Institute

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer

Predicting Significance of EGFR Mutation Existing in Tissues and Plasma Concuurrently or Alone to EGFR–tyrosine Kinase Inhibitors (Egfr-Tkis) for Advanced Non-Small Cell Lung Cancer.

Correlation between EGFR mutation status and the efficacy of first-line chemotherapy in advanced lung adenocarcinoma

The Relationship Between EGFR Gene Copy Number and EGFR Mutation and Clinical Predicting Significance in the Chinese Patients with Advanced Non-Small Cell Lung Cancer Patients.

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis

Intratumoral Heterogeneity of EGFR Mutation and Clinical Significance in Chinese Patients with Advanced Non-Small Cell Lung Cancer.